Citizens JMP raised the firm’s price target on Aquestive Therapeutics (AQST) to $12 from $9 and keeps an Outperform rating on the shares. Aquestive announced the issuance of two additional patents for Anaphylm, extending brand exclusivity through at least 2037, the analyst tells investors in a research note. The patents are meaningfully value accretive as they cover compositions of matter for the novel epinephrine prodrug used in the product candidate, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Aquestive Therapeutics Highlights at Global Investor Conference